People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits

- A new Harris Poll survey finds the majority of adults in the U.S. who exercise intensely understand the importance of maintaining hydration throughout a workout (93%) and that hydration is important for muscle recovery (89%), yet many have misconceptions about the type of hydration that may impact their ability to perform and recover optimally.

The survey conducted for Abbott (NYSE: ABT) found 46% of people who report regular, intense exercise at least three days per week believe that energy drinks and soda can aid in rehydration after a strenuous 4 workout. This conflicts with guidance from the scientific community that these drinks can contribute to dehydration due to large amounts of sugar and insufficient levels of electrolytes. 1,2,3

Understanding the Science Behind Hydration and Its Impact on Performance
During a workout, dehydration occurs when fluid losses – whether from sweating, increased core temperatures or even breathing – exceed fluid consumed through both foods and drinks. Fluid loss is also accompanied by the loss of electrolytes, which are minerals that aid in healthy cell signaling and function. 5,6

"Water makes up nearly 75 percent of every cell in your body, making its replacement during and after exercise essential to everyday health," said Craig Horswill , Ph.D., clinical associate professor in the Department of Kinesiology and Nutrition at the University of Illinois at Chicago . "What many don't realize is that electrolytes also help direct the flow of water in and out of cells, helping to support rehydration and muscle repair. Carbohydrates like glucose are needed to pull the electrolytes and water into the body during rehydration, yet too much sugar can slow rehydration and delay recovery."

Smart Hydration
Abbott, maker of Pedialyte, and Jeanette Jenkins , human kinetics expert and one of the nation's leading health and fitness coaches, are encouraging fitness enthusiasts to focus on the quality of an electrolyte beverage because ingredients can impact hydration status and how muscles function and recover.

"I tell my clients that to get results, they need to be mindful of both their food and beverage choices as part of their workout preparation and recovery," said Jenkins, who has trained professional athletes, including professional basketball champions. "It's important to approach hydration with intention; get plenty of water and hydrating liquids like Pedialyte each day before, during and after a workout and track your progress on overall nutrition and health goals."

In 2020, Abbott's Pedialyte launched a new rehydration solution scientifically designed for athletes with five key electrolytes for muscle support. Offering three times the electrolytes and one-fourth the sugar of the leading sports drink, 7 Pedialyte Sport was developed to help athletes avoid negative symptoms of mild to moderate dehydration like muscle cramping, fatigue and headache by replacing fluid/water lost in sweat. It has an optimal balance of glucose and sodium, which is critical to the rehydration process. Electrolytes also support fluid balance in the body and are vital to muscle and nerve function, as well as help facilitate muscle repair. 1

"Abbott continues to advance Pedialyte's formulations, which were originally created to help prevent mild to moderate dehydration in sick children," said Chris Calamari , senior vice president of U.S. nutrition at Abbott. "As the number one, doctor-recommended electrolyte solution, adults, athletes and trainers recognize the science behind this product, which led us to develop Pedialyte Sport. Created specifically for athletes, Pedialyte Sport is designed for fast rehydration and replenishment of fluid and electrolytes during recovery."

About Pedialyte
Pedialyte Sport is available in ready-to-drink bottles and powder packs in both lemon-lime and fruit punch flavors. Pedialyte products can be found online and in-store at most major retailers, including Walmart, Target and Amazon. Other Pedialyte products include AdvancedCare ® Plus with PreActiv ® Prebiotics; Pedialyte Organic , a U.S. Department of Agriculture certified organic electrolyte solution; Pedialyte with Immune Support with vitamins C, E, B 12 and zinc; and Pedialyte Electrolyte Water with zero sugar 8 designed for everyday hydration. For more information about hydration, visit the Abbott Nutrition Health Institute , and for product information, visit Pedialyte.com .

About the Survey
This survey was conducted online within the U.S. by The Harris Poll on behalf of Abbott from April 27-29, 2021 , among 2,047 U.S. adults ages 18 and older, of whom, 799 typically participate in intense exercise at least three days per week. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

1 Baker LB, Jeukendrup AE. Optimal Composition of Fluid-Replacement Beverages. Compr Physiol. 2014(4):575-620.
2 McDermott BP, et al. National Athletic Trainers' Association Position Statement: Fluid Replacement for the Physically Active. J Athl Train. 2017;52(9):877-895.
3 Sawka MN, et al. Exercise and Fluid Replacement. American College of Sports Medicine Position Stand. Med Sci Sports Exer 2007;39(2):377-90. doi: 10.1249/mss.0b013e31802ca597.
4 Strenuous is defined as requiring maximum effort (e.g., lasting approximately 30 minutes or more and resulting in a substantially higher heart rate as compared with resting heart rate and rapid breathing making it difficult to speak in full sentences). Exertion levels considered hard to extremely hard.
5 Dehydration Symptoms & Causes, Pedialyte.com
6 Liska et al. Narrative review of hydration and selected health outcomes in the general population. Nutrients 2019(11):1-29
7 Pedialyte ® Sport has 1380 mg sodium and no more than 14g sugar per liter; the leading sports drinks has ~460 mg sodium and ~58 g sugar per liter.
8 Low in calories.

Cision View original content: https://www.prnewswire.com/news-releases/people-who-exercise-intensely-could-improve-recovery-by-adjusting-their-hydration-habits-301319344.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform.

(PRNewsfoto/Medtronic plc)

The submissions included a 510(k) application for its MiniMed™ 780G pump as an alternate controller enabled (ACE) insulin pump and a separate 510(k) application for its SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC).

"We understand how meaningful these advancements are, and we're working with urgency to bring enhanced CGM options to our customers," said Que Dallara, EVP & president, Medtronic Diabetes. "This collaboration with Abbott marks an important step forward in providing innovative solutions and more choice for our customers."

This milestone follows the announcement last August that the companies will collaborate on an integrated system based on Abbott's most advanced CGM platform. Abbott will supply Medtronic with a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and smart multiple daily injections systems. These systems, including the Abbott CGM, will be sold exclusively by Medtronic.

More details will be shared when FDA clearance is secured.

About the Diabetes Business at Medtronic ( www.medtronicdiabetes.com )
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn .

Any forward-looking statements, including, but not limited to, statements regarding the partnership between Medtronic and Abbott, strategic and other potential benefits of the partnership, Abbott's products and product candidates, and other statements about Medtronic managements' future expectations, beliefs, goals, plans or prospects, are subject to risks and uncertainties including, but not limited to, the ability to obtain regulatory approvals, and other risks and uncertainties such as those described in Medtronic's reports and other filings with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Medtronic cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this document, and Medtronic undertakes no obligation to update or revise any of these statements except to the extent required by law.

Contacts:
Janet Cho
Public Relations
+1-818-403-7028

Ryan Weispfenning
Investor Relations
+1-763-505-4626

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-advances-abbott-cgm-partnership-with-fda-submission-of-interoperable-insulin-pump-302437337.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

  • FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk
  • HRS Satellite Symposium will feature leading experts in electrophysiology, hypertension management and heart failure
  • Presentations will detail clinical results from prior studies demonstrating AVIM therapy's ability to immediately, substantially and persistently reduce systolic blood pressure, as well as improve cardiac function
  • Symposium will also feature presentation on the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT)

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society ("HRS") 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company's atrioventricular interval modulation ("AVIM") therapy program. The April 25 th 6:45 am PT symposium titled " The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy " will convene leading electrophysiologists, hypertension and heart failure specialists to discuss the unmet need in hypertension, AVIM therapy mechanism of action, and growing body of clinical evidence supporting this novel therapy for the treatment of patients with uncontrolled hypertension who have increased cardiovascular risk with or without an indication for a pacemaker.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

  • Breakthrough Device Designation ("BDD") applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk
  • BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension who are the focus of the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc (NYSE: MDT)
  • BDD status provides accelerated FDA engagement and reviews for AVIM therapy; it also supports potential pathways to secure higher reimbursement for AVIM-enabled devices in the future

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Device Designation ("BDD") for atrioventricular interval modulation ("AVIM") therapy.

Specifically, the BDD is for an implantable system (i.e., a pacemaker) to deliver AVIM therapy using conduction system pacing to reduce blood pressure in patients with increased ten-year atherosclerotic cardiovascular disease ("ASCVD") risk, preserved left ventricular systolic function, and uncontrolled hypertension, despite the use of anti-hypertensive medications or in patients who may have intolerance to anti-hypertensive medications. Orchestra BioMed estimates that there are over 7.7 million patients in the U.S. that meet the criteria for the BDD for AVIM therapy. AVIM therapy is currently being evaluated under an FDA investigational device exemption ("IDE") in the BACKBEAT global pivotal study which is being conducted by Orchestra BioMed in collaboration with Medtronic. The BACKBEAT pivotal study is enrolling pacemaker-indicated patients with uncontrolled hypertension despite the use of anti-hypertensive medication, a key subpopulation under the BDD for which Orchestra BioMed believes AVIM therapy may offer optimal clinical benefit.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
New Simplera Sync sensor for the MiniMed 780G System now FDA approved

New Simplera Sync sensor for the MiniMed 780G System now FDA approved

Latest approval expands Medtronic CGM portfolio in the U.S.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection™ technology with both the Guardian™ 4 sensor and Simplera Sync™ sensor.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today's AI-driven world, the use of deep learning algorithms and AI tools in diagnostics can improve the accuracy, speed and efficiency for diagnosing patients with minimal errors. The introduction of AI tools in diagnostics has revolutionized the healthcare industry with supporting the doctors in advanced disease diagnosis and providing personalized treatments to patients with better judgements and quick results. According to Precedence Research, the global artificial intelligence in diagnostics market size was exhibited at USD 1.61 billion in 2024 and is projected to hit around USD 8.54 billion by 2033, growing at a CAGR of 20.37% during the forecast period 2024 to 2033. The report said: "The advances in digital biomarkers technology which uses real-time monitoring systems for early disease diagnosis and prediction has also enhanced the AI in diagnostics market growth. The application of AI tools in diagnostics has led to analyzing medical images for assessing disease progression, predicting patient outcomes, processing and storing of patient data which includes electronic health records (EHRs), identifying patterns and anomalies in patient data and symptom checkers for providing potential diagnosis."   Active healthcaretech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Illumina Inc. (NASDAQ: ILMN), Tempus AI, Inc. (NASDAQ: TEM), Medtronic plc (NYSE: MDT), Spectral AI, Inc. (NASDAQ: MDAI).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the JACC, the flagship journal of the American College of Cardiology .

The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. These patients had a predicted 30-day mortality risk

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×